Advertisement

Bulletin of Experimental Biology and Medicine

, Volume 168, Issue 2, pp 280–284 | Cite as

Marker Systems Based on MicroRNA Gene Methylation for the Diagnosis of Stage I-II Breast Cancer

  • E. A. BragaEmail author
  • E. A. Filippova
  • V. I. Loginov
  • I. V. Pronina
  • A. M. Burdennyi
  • T. P. Kazubskaya
  • M. V. Fridman
  • D. S. Khodyrev
  • N. E. Kushlinskii
Article
  • 2 Downloads

Groups of microRNA genes, methylation of which is associated with the initial (I-II) stages of breast cancer, are determined, and new markers and marker systems for the disease diagnosis were created on the basis of these data. A total of 14 genes in which methylation was associated with breast cancer were identified with the use of methyl-specific PCR on a representative sample of 70 tumor specimens. Analysis of 46 specimens from patients with clinical stages I and II detected 9 genes (MIR-124-1, MIR-124-3, MIR-125b-1, MIR-129-2, MIR-132, MIR-148a, MIR-193a, MIR-34b/c, and MIR-9-3), in which methylation was associated with the initial stages of the disease. Using ROC analysis, we formed two systems including 6 markers each and detecting breast cancer at stages I-II with high sensitivity (89 and 91%) and specificity (88%) at AUC=0.92-0.93. These sets were validated on the total sample of 70 specimens including all disease stages; they showed 93 and 94% sensitivities, 88% specificity, and AUC=0.95. Highly sensitive systems of markers, based on microRNA gene methylation, were created for the diagnosis of breast cancer at stages I-II.

Key Words

microRNA genes hypermethylation breast cancer ROC analysis diagnostic marker systems 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Braga EA, Loginov VI, Burdennyi AM, Filippova EA, Pronina IV, Kurevlev SV, Kazubskaya TP, Kushlinskii DN, Utkin DO, Ermilova VD, Kushlinskii NE. Five Hypermethylated MicroRNA Genes as Potential Markers of Ovarian Cancer. Bull. Exp. Biol. Med. 2018;164(3):351-355. doi:  https://doi.org/10.1007/s10517-018-3988-y CrossRefPubMedGoogle Scholar
  2. 2.
    Braga EA, Loginov VI, Pronina IV, Burdennyy AM, Kubatiev AA, Khodyrev DS, Rykov SV, Friedman MV, Kazubskaya TP, Kushlinskii NE. Upregulation of RHOA and NKIRAS1 genes in lung tumors is associated with loss of their methylation as well as with methylation of regulatory miRNA genes. Biochemistry (Moscow). 2015;80(4):483-494.CrossRefPubMedGoogle Scholar
  3. 3.
    Braga EA, Loginov VI, Filippova EA, Burdennyi AM, Pronina IV, Kazubskaya TP, Khodyrev DS, Utkin DO, Kushlinskii DN, Adamyan LV, Kuslinskii NE. Diagnostic Value of a Group of MicroRNA Genes Hypermethylated in Ovarian Carcinoma. Bull. Exp. Biol. Med. 2018;166(2):253-256. doi:  https://doi.org/10.1007/s10517-018-4326-0 CrossRefPubMedGoogle Scholar
  4. 4.
    Malignant Neoplasms in Russia in 2017 (Morbidity and Mortality). Karpin AD, Starinskii VV, Petrova GV, eds. Moscow, 2018. Russian.Google Scholar
  5. 5.
    Loginov VI, Beresneva EV, Kazubskaya TR, Braga EA, Karpukhin AV. Methylation of 10 miRNA genes in clear cell renal cell carcinoma and their diagnostic value. Onkourologiya. 2017;13(3):27-33. Russian.CrossRefGoogle Scholar
  6. 6.
    Campos-Parra AD, Mitznahuatl GC, Pedroza-Torres A, Romo RV, Reyes FIP, López-Urrutia E, Pérez-Plasencia C. Micro-RNAs as potential predictors of response to breast cancer systemic therapy: future clinical implications. Int. J. Mol. Sci. 2017;18(6). pii: E1182. doi: 10.3390/ijms18061182CrossRefPubMedCentralGoogle Scholar
  7. 7.
    Dey S. Preventing breast cancer in LMICs via screening and/or early detection: The real and the surreal. World J. Clin. Oncol. 2014;5(3):509-519.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Khordadmehr M, Shahbazi R, Ezzati H, Jigari-Asl F, Sadreddini S, Baradaran B. Key microRNAs in the biology of breast cancer; emerging evidence in the last decade. J. Cell. Physiol. 2019;234(6):8316-8326.CrossRefPubMedGoogle Scholar
  9. 9.
    Kunej T, Godnic I, Ferdin J, Horvat S, Dovc P, Calin GA. Epigenetic regulation of microRNAs in cancer: An integrated review of literature. Mutat. Res. 2011;717(1-2):77-84.CrossRefPubMedGoogle Scholar
  10. 10.
    Liu B, Liu Y, Luo X, Pan Y, Yang L, Li F, Gao R, Chen W, He J. MicroRNA-195 as a diagnostic biomarker in human cancer detection: A meta-analysis. Oncol. Lett. 2018;16(5):6253-6260.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Piletič K, Kunej T. MicroRNA epigenetic signatures in human disease. Arch. Toxicol. 2016;90(10):2405-2419.CrossRefPubMedGoogle Scholar
  12. 12.
    Pronina IV, Loginov VI, Burdennyy AM, Fridman MV, Senchenko VN, Kazubskaya TP, Kushlinskii NE, Dmitriev AA, Braga EA. DNA methylation contributes to deregulation of 12 cancer-associated microRNAs and breast cancer progression. Gene. 2017;604:1-8.CrossRefPubMedGoogle Scholar
  13. 13.
    Vrba L, Muñoz-Rodríguez JL, Stampfer MR, Futscher BW. miRNA gene promoters are frequent targets of aberrant DNA methylation in human breast cancer. PLoS One. 2013;8(1). ID e54398. doi: 10.1371/journal.pone.0054398CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    WHO Classification of Tumours of Female Reproductive Organs. Kurman RJ, Carcangiu ML, Herrington CS, Young RH, eds. Lyon, 2014.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • E. A. Braga
    • 1
    • 2
    Email author
  • E. A. Filippova
    • 1
  • V. I. Loginov
    • 1
    • 2
  • I. V. Pronina
    • 1
  • A. M. Burdennyi
    • 1
  • T. P. Kazubskaya
    • 3
  • M. V. Fridman
    • 4
  • D. S. Khodyrev
    • 5
  • N. E. Kushlinskii
    • 3
  1. 1.Research Institute of General Pathology and PathophysiologyMoscowRussia
  2. 2.Medical Genetic Research CenterMoscowRussia
  3. 3.N. N. Blokhin National Medical Research Center of OncologyMinistry of Health of the Russian FederationMoscowRussia
  4. 4.N. I. Vavilov Institute of General GeneticsRussian Academy of SciencesMoscowRussia
  5. 5.Federal Research Clinical Center of Specialized Types of Medical Care and Medical TechnologiesFederal Biomedical Agency of RussiaMoscowRussia

Personalised recommendations